Definiens AG, a Munich, Germany-based provider of a tissue diagnostics platform aimed at helping physicians improve treatment, closed a €15m financing round.
The round was led by Wellington Partners and Gilde Healthcare with participation from existing investors Cipio Partners and TVM Capital. In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens’ Board of Directors.
The company intends to use the funds to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing its Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer.
Led by Thomas Heydler, CEO, and Dr. Gerald Möller, Chairman, Definiens has developed technology for discovery and diagnostics development in oncology and provides image analysis solutions for life sciences. Its platform provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists with detailed tissue biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information (an approach known as Tissue Phenomics™) to generate new knowledge and support better decisions in research, diagnostics and therapy.
The company has its North American headquarters in Carlsbad, CA.